Concourse Financial Group Securities’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Concourse Financial Group Securities’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$226	–	2169
2024 Q4	$226	Hold	100	–	–	﹤0.01%	2189
2024 Q3	$368	Hold	100	–	–	﹤0.01%	2161
2024 Q2	$409	Hold	100	–	–	﹤0.01%	2217
2024 Q1	$1.58K	Hold	100	–	–	﹤0.01%	2077
2023 Q4	$1.51K	Hold	100	–	–	﹤0.01%	2063
2023 Q3	$2.01K	Hold	100	–	–	﹤0.01%	1999
2023 Q2	$2.82K	Hold	100	–	–	﹤0.01%	1962
2023 Q1	$1.72K	Hold	100	–	–	﹤0.01%	2083
2022 Q4	$2.01K	Hold	100	–	–	﹤0.01%	2032
2022 Q3	$2K	Hold	100	–	–	﹤0.01%	1830
2022 Q2	$3K	Buy	+100	New	+$2.65K	﹤0.01%	1984

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concourse Financial Group Securities's ZNTL Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 100 shares — an estimated $226 sold.

Concourse Financial Group Securities first reported a position in ZNTL in Q2 2022 and held it in 11 quarters. The position peaked at $3K in Q2 2022. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

Concourse Financial Group Securities reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Concourse Financial Group Securities sold 100 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $226.
Concourse Financial Group Securities first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Concourse Financial Group Securities's Zentalis Pharmaceuticals position peaked at $3K in Q2 2022.
132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.